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Abstract 
Nephrogenic syndrome of inappropriate diuresis is a recently-discovered rare disease caused 
by gain-of-function mutations of the V2 vasopressin receptor gene, AVPR2. To date, 
mutations of Phe229 and Arg137 have been identified as gain-of-function mutations in V2 
vasopressin receptor (V2R). The mutant receptors lead to hyponatremia, which may lead to 
clinical symptoms in infants. In this study, we present a newly-identified Ile130Asn (I130N) 
substitution, causing NSIAD in a family. Characterization of the mutation revealed basal 
constitutive activity of V2R. We have demonstrated that the I130N mutation results in 
constitutive cAMP generation in HEK293 cells. Basal activity of the mutant receptor could 
be blocked by the inverse agonist tolvaptan and arginine-vasopressin stimulation enhanced 
the cAMP production of I130N-V2R. The mutation causes a biased receptor conformation 
since the basal cAMP generation activity of I130N does not lead to interaction with β-
arrestin. The constitutive activity of the mutant receptor causes constitutive dynamin-
dependent and β-arrestin-independent internalization. The inhibition of the basal 
internalization using dominant-negative dynamin resulted in an increased cell surface 
expression. In contrast to the constitutive internalization, agonist-induced endocytosis was β-
arrestin dependent. Based on our findings, tolvaptan could be used for treatment of 
hyponatremia, shown in patients with nephrogenic syndrome of inappropriate diuresis who 
carry the I130N-V2R mutation.  
Introduction 
Mutations in G protein-coupled receptors (GPCR) may lead to broad spectrum of human 
diseases (1). The recently discovered nephrogenic syndrome of inappropriate antidiuresis 
(NSIAD) is caused by gain-of-function mutations in the AVPR2 gene affecting the V2R (2). 
V2R is expressed in the plasma membrane of the principal cells in the kidney and mediates 
3 
 
the effect of the water homeostasis regulator arginine-vasopressin (AVP) through Gs-
dependent cAMP production via adenylyl cyclase activation. Binding of AVP to the V2R 
leads to cAMP-mediated translocation of aquaporin-2 to the apical plasma membrane. This 
regulation of aquaporin-2 water channel localization is crucial for increasing urine osmolality 
and reducing urine output in humans  (3). For precise regulation, the signal transduction of 
the activated GPCR has to be terminated to limit the effect in the target cells (4). Impairment 
of these processes may result in receptor dysfunction and disease, such as nephrogenic 
diabetes insipidus (NDI) in case of V2R (5). 
 Although more than 200 loss-of-function mutations affecting V2R have been 
identified (6), fewer NSIAD-causing gain-of-function mutations have been described. The 
first mutations were identified in infants who suffered from irritability and generalized 
seizures, resulting in substitutions of Arg137 to either Cys or Leu in the V2R (R137C or 
R137L) (2). The mutations caused elevated basal cAMP production in cells expressing the 
mutant receptors. Basal activity of R137C and R137L mutant V2Rs had similar properties to 
the NDI-causing R137H missense mutation, since the conformation of the mutant receptors 
also induced agonist-independent β-arrestin2 interaction (5, 7). Characterization of the 
R137C/L mutants revealed that although AVP stimulation caused increased β-arrestin 
binding, the agonist-induced cAMP generation was negligible, despite the affinity of the 
mutants toward AVP being unchanged (8). The data of Rochdi et al. may explain the clinical 
finding, that both the R137C and R137L mutations were insensitive to acute inverse agonist 
tolvaptan treatment (9, 10). Recently, a new NSIAD-causing substitution (F229V) in the V2R 
was found (11). Although F229V mutation was shown to have increased basal cAMP 
production, F229V-V2R had no detectible constitutive β-arrestin binding. F229V-V2R has a 
different constitutive active conformation from R137C/L receptors, since the cAMP 
generation could be further increased upon AVP stimulation. Moreover, the basal activity 
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could be blocked with inverse agonists. Another putative NSIAD mutation, V266A, has been 
reported, but it is considered to be a neutral polymorphism (12, 13). The patients with NSIAD 
at greatest risk are neonates and infants, who are vulnerable to hyponatremia and the 
consequent seizures (10, 14, 15). Therefore, a proposed therapeutic strategy based on 
functional studies of the mutant V2Rs could help these patients to minimize possible dangers 
of this genetic condition.  
Here, we present a novel gain-of-function mutation of the V2R, identified in a patient and his 
family with hyponatremia. Functional studies were carried out to characterize the properties 
of the I130N-V2R. We demonstrate that the cellular effects of this mutation are different 
from those of previously described NSIAD-causing mutations. Based on our functional 
findings, a therapeutic recommendation could be proposed for patients carrying the I130N 
mutation.  
Results 
Identification of the I130N mutation in the AVPR2 gene 
The index patient was a 34-year old male with a long history of hyponatremia. Low sodium 
levels were first diagnosed at age 28 as part of a routine examination. Infancy and childhood 
of the patient was unremarkable. Except for occasional palpitations the patient was free of 
complaints. Further medical history included a tonsillectomy, pollen allergy, but not cerebral 
trauma or neuropsychological abnormalities. Medication at time of presentation was 
Nebivolol 2.5 mg/day, which was started at age 31 due to palpitations. No abnormal physical 
findings were noted; especially no edema or changes of skin color were detected. The 
average estimated fluid intake was 2-3 liters per day. Laboratory findings are shown in Table 
1. AVP levels were low; sodium excretion in 24 h urine was elevated in an euvolemic state. 
The patient had marked hyponatremia in combination with low AVP levels compatible with 
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the diagnosis NSIAD, however this diagnostic entity is still under discussion (2). We studied 
the family of the index patient (Fig. 1). Two family members had low sodium levels: the 
mother and grandmother of the index patient, whereas father and sister had normal sodium 
levels (Table 2), consistent with an X-linked inheritance pattern of the disorder. All family 
members were in good general health, apart from degenerative joint and back complaints 
(I.2). Since the data confirmed the familial hyponatremia, we performed a molecular 
mutation analysis of the vasopressin type-2 receptor gene (AVPR2). Mutation analysis by 
direct DNA sequencing of PCR fragments from the proband and his family revealed a novel 
missense mutation, c.389T>A in exon 2 of the AVPR2 gene, which results in the amino acid 
change p.Ile130Asn. The proband was hemizygous for the mutation, whereas his mother 
(II.2), his sister (III.2) and his grandmother (I.2) were heterozygous for the p.Ile130Asn 
mutation confirming their carrier status. His father (II.1) showed a wild type sequence of the 
AVPR2 gene. The mutation was predicted by the Mutation Taster software to be “disease-
causing” (probability score 0.999) and has not been previously recorded neither in the dbSNP 
database (www.ncbi.nlm.nih.gov/SNP/) nor in the NHLBI Exome Variant Server Database 
(http://evs.gs.washington.edu/EVS/). 
Determination of cellular localization of the I130N-V2R 
Confocal microscopy was implemented in order to determine the cellular localization of the 
I130N-V2R. The plasma membrane marker containing consensus sequence for 
myristoylation and palmitoylation (MP-Cerulean), the nuclear localization signal (NLS-
mRFP) and either the WT-V2R or the I130N-V2R tagged with mVenus were transiently 
expressed in HEK293 cells (Fig. 2A). The mutant receptor showed similar intracellular 
fluorescence to the wild type receptor but the plasma membrane localization was less 
pronounced. For the conformation of the plasma membrane expression of the mutant receptor 
immunostaining with anti-HA-Alexa488 was performed in non-permeabilized cells co-
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expressing NLS-mRFP and either HA-WT-V2R or HA-I130N-V2R (Fig. 2B). Confocal 
imaging clearly showed plasma membrane localization of the mutant receptor.  
Investigation of the cAMP production of the I130N-V2R 
For functional characterization, we monitored the cAMP production using BRET technique. 
Loading the Epac domain with cAMP causes conformational changes that move away the 
energy acceptor from the donor. Consequently, an increase in intracellular cAMP level results 
in a decreased BRET ratio in our measurements. As described previously, an increased 
cAMP concentration resulted in a decreased BRET ratio using the Epac-BRET sensor (16). 
Real-time monitoring of the cAMP levels were performed in living HEK293 cells expressing 
one of the following receptors: wild type receptor, I130N-V2R or N321K mutant receptor 
(this loss-of-function mutation has been characterized previously, reflecting the absence of 
basal activity) (16). The cells were treated first with tolvaptan, then with AVP (Fig. 3A-B). 
The basal BRET ratios were different for the various receptors, reflecting diverse basal 
cAMP levels. Wild-type (rectangle) showed known basal activity (16, 17). The basal BRET 
ratio of the I130N-V2R was markedly decreased, indicating constitutive activity of this 
mutant receptor (circle). Treatment of the wild-type and I130N receptor with the inverse 
agonist resulted in a decreased cAMP concentration (filled marks). Wild-type and I130N 
receptor stimulation with AVP resulted in a robust cAMP response (similar to forskolin 
treatment, Suppl. 2) and the kinetics of the cAMP response was similar.  Fig. 3B shows the 
average of BRET ratios before and after stimulation. The dose-response curve of tolvaptan 
effect on the basal receptor activity was also determined. The inverse agonist tolvaptan had 
larger efficacy in case of the I130N-V2R mutant compared to the wild type receptor and 
potency was also determined (pEC50:-7.94 ± 0.07 M for I130N-V2R, -8.15 ± 0.03 M forWT-
V2R (Fig. 3C)). 
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Characterization of the plasma membrane expression of the I130N-V2R 
Since constitutive activity could affect the presence of the receptor in the plasma membrane, 
we examined internalization properties. We performed flow cytometry measurements in 
order to assess the receptor quantity in plasma membrane of the cells. The relative fluorescent 
intensity (RFI) of the I130N mutant receptor (RFI: 0.59±0.1) was significantly lower than the 
RFI of the wild type receptor (RFI: 1.0) indicating decreased plasma membrane presence 
(Fig. 4A, n=4, p<0.05). We performed BRET measurements to monitor the change in 
receptor density in the plasma membrane. Cells were transfected with either WT-V2R or 
I130N-V2R tagged with Sluc bioluminescent donor (Renilla luciferase) and YFP-tagged 
plasma membrane marker containing consensus sequence for myristoylation and 
palmitoylation (MP-YFP). The non-specific energy transfer (BRET ratio) depends on the 
distance between the bioluminescent donor (receptor) and fluorescent acceptor (plasma 
membrane). Consequently, the decreased the BRET ratio reflects the altered localization of 
the energy donor and the acceptor, indicating the internalization of the cell surface localized 
receptors (16, 18, 19). Reflecting the flow cytometry data, there is remarkable difference 
between the basal BRET ratio of the wild type (Fig 4B, rectangle) and I130N receptor 
(circles), indicating a decreased plasma membrane presence of the mutant. Since the Sluc 
counts depend on the expression of the Sluc enzyme in the presence of the cell permeable 
substrate coelenterazine, the comparison of the normalized Sluc counts reflect the total 
protein level of the tagged receptors. The Sluc counts of WT-V2R and I130N-V2R were 
similar in the BRET measurements after the addition of cell permeable substrate reflecting 
that there was no significant difference in the level of the fused proteins (Suppl. 2). Tolvaptan 
could evoke a significant increase in the BRET ratio of the I130N-V2R. Next, we examined 
the agonist induced internalization of the receptor. Fig. 4C shows a robust fall in the BRET 
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ratios in the cells expressing the WT-V2R and the I130N mutant receptor in response to AVP 
treatment (filled marks).  
Examination of the β-arrestin2 binding  
We investigated the properties of the constitutive internalization of the I130N-V2R in detail. 
We compared the basal and agonist dependent β-arrestin2 binding of the wild-type and I130N 
mutant receptor with BRET technique. There was no difference in the basal BRET ratios 
(Fig. 5), which indicates the lack of β-arrestin2 binding of the constitutive active receptor. In 
accordance with that, tolvaptan treatment did not alter basal β-arrestin2 binding (data not 
shown). AVP stimulation yielded an increase in the BRET ratio between β-arrestin2 and the 
I130N-V2R, which was reduced than of WT-V2R (Fig. 5A).  
Investigation of the internalization properties 
We investigated the effect of dominant-negative dynamins in order to characterize the 
internalization properties of the I130N-V2R (8, 11). The wild-type dynamin1 could be used 
as a control, since there was no difference between the cotransfection of empty pcDNA3.1 or 
dynamin1 (Suppl. 3). Cells expressing the dominant-negative dynamin1 (Fig. 5B, DNdyn1-
square) show an increased BRET ratio between the I130N-V2R-Sluc and the plasma 
membrane marker MP-YFP, compared to the effect of wild-type dynamin1 (dyn1, circle). 
Tolvaptan treatment could increase the plasma membrane presence of I130N-V2R-Sluc in the 
dominant-negative dynamin1 expressing cells (Fig 5B, filled rectangle), however this 
elevation was less than that of wild type dynamin1 expressing cells (filled circle).  
Discussion 
In this study, we present a novel gain-of-function mutation of the V2R, which we identified 
in a NSIAD patient with hyponatremia and low AVP levels. Sequencing of the AVPR2 gene 
9 
 
revealed a missense mutation causing the amino acid substitution, p.Ile130Asn in the receptor 
(I130N-V2R). Characterization of the I130N-V2R revealed high basal concentration of 
cAMP in the cells expressing the mutant receptor (Fig. 3A-B). This constitutive activity of 
the mutant receptor could be blocked with the inverse agonist tolvaptan. This property of the 
I130N-V2R was similar to the consequence of the reported F229V mutation (11).  
Importantly, the treatment with tolvaptan instantly reduced the basal cAMP production of the 
receptor, which may raise the possibility of using tolvaptan in the therapy of NSIAD patients 
with I130N and similar mutations. In contrast to the R137C/L mutants, I130N-V2R showed 
increased cAMP production upon AVP stimulus (Fig 3A-B, (8)). Fig. 5A demonstrates that 
the I130N-V2R is capable of agonist-induced β-arrestin2 binding, while the constitutively 
active conformation, in spite of robust basal cAMP production, did not provoke detectible 
basal β-arrestin2 binding. Taken together, the constitutive active conformation of I130N-V2R 
in the absence of AVP differs from the agonist-induced active conformation of the receptor 
and clearly differs from the AVP-induced conformation of the wild-type receptor. In this 
regard, the I130N-V2R is similar to the F229V-V2R, since both share the characteristic 
property of the lack of basal β-arrestin2 binding, but not to R137C and R137L (7, 8, 11). 
These findings indicate that the I130N missense mutation can be considered as a biased 
mutant V2R, since the G-protein dependent pathway can be selectively activated. This 
phenomenon fit in the concept that GPCRs may have multiple active conformations with 
altered characteristics (20).  
Confocal microscopy revealed a plasma membrane localization of the I130N-V2R and 
intracellular vesicles could not be identified (Fig. 2). This observation was similar to the 
cellular distribution of the F229V mutant (11) and it can be explained by the lack of basal β-
arrestin binding of the I130N-V2R. However, the measurement of the plasma membrane 
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density of the mutant with flow cytometry showed reduced cell surface presence of the 
I130N-V2R (Fig 4A).  
We also investigated the internalization properties of the mutant receptor (18, 21). The 
agonist stimulation induced a decrease in the BRET ratio, which indicates rapid 
internalization of the I130N-V2R (Fig 4C). Consistently with the flow cytometry 
measurements, the lower basal BRET ratio of I130N-V2R-Sluc with MP-YFP reflects the 
decreased plasma membrane localization, which could be further reduced upon AVP 
stimulus. Tolvaptan resulted in a slow increase of the BRET ratio between the I130N-V2R-
Sluc and MP-YFP, but not in the cells expressing the wild type receptor (Fig 4B). Therefore, 
the constitutive activity of the I130N-V2R not only affects cAMP production, but also leads 
to internalization of the receptor, which could be blocked with inverse agonist tolvaptan. In 
contrast to the R137C/L mutants, I130N-V2R does not bind β-arrestin in the absence of 
agonist, but shows constitutive internalization, which can be inhibited with tolvaptan. This 
later observation suggests that the I130N mutation leads to different conformation from 
F229V mutation. Carpentier et al. concluded, that F229V mutation does not increase 
constitutive internalization of the receptor, although only receptor/β-arrestin and β-
arrestin/AP2 interaction were measured with dominant negative dynamin or agonist 
treatment, and it was not shown whether the inverse agonists could affect the cell surface 
expression of the mutant (11). The dissimilarity in the agonist induced and constitutive 
internalization observed in this study in case of I130N-V2R is not unique among GPCRs, 
since β-arrestin-dependent, agonist-induced endocytosis and β-arrestin-independent 
constitutive internalization was introduced earlier (22-24). It is also notable, that basal 
internalization is not obviously a consequence of constitutive activity (25).  
We examined the role of dynamin in the basal endocytosis to investigate the β-arrestin 
independent constitutive internalization. The expression of dominant-negative dynamin 
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resulted in increased plasma membrane localization I130N-V2R (Fig. 5B). Moreover, the 
effect of tolvaptan on constitutive internalization was less dramatic, compared to cells 
expressing wild-type dynamin. These data suggest that although basal endocytosis is β-
arrestin-independent, it involves dynamin. Dominant-negative dynamin was shown to 
increase cell surface expression and β-arrestin/AP2 interaction of R137C/L receptors, which 
raises the possibility that the mutant receptors were trapped in the plasma membrane and 
accumulated in receptor-β-arrestin-AP2 complex (8). In contrast, F229V-V2R did not show 
increased β-arrestin/AP2 interaction in the case of co-expression of dominant-negative 
dynamin. This result was consistent with the absence of basal β-arrestin binding. The cell 
surface expression of the F229V in the presence of dominant-negative dynamin was not 
shown in this study (11). The internalization properties of I130N-V2R in the absence of 
agonist are not without example among the GPCRs. As it was described earlier, endocytotic 
pathways appear to function with plasticity and there is β-arrestin-independent but dynamin-
dependent internalization mechanisms (26-29). 
In this study, we identified and characterized a new gain-of-function mutation of the V2R, 
which leads to NSIAD. The mutation leads to biased receptor conformation (Fig. 6). The 
I130N mutation was shown to lead to increased intracellular cAMP concentration. Since the 
constitutive internalization of I130N-V2R was dynamin-dependent but β-arrestin-
independent, the G-protein dependent pathway can be selectively activated in this mutant 
receptor. Inhibition of the basal internalization resulted in an increased cell surface density. 
Based on our findings, tolvaptan could be used for treatment of hyponatremia and its 
consequences such as seizures in patients with NSIAD and carrying I130N-V2R mutation.  
Materials and methods 
Mutation analysis in the AVPR2 gene 
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Family history, clinical and laboratory data and signed informed consent were obtained from 
the index patient and his relatives. Mutation analysis in the AVPR2 gene was performed via 
PCR and Sanger sequencing of the entire coding region of the gene and flanking intron-exon 
boundaries. PCR primer sequences were based on those previously published by Chen et al. 
(30). The database sequence NM000054 (transcript ENST337474) was used as reference 
sequence for AVPR2. Prediction of mutation disease-causing status was performed using the 
mutation taster algorithm (www.mutationtaster.org). 
Molecular biology 
Details of generation of the molecular biological constructs were described previously (16).  
Standard site-directed mutagenesis techniques were used to perform mutagenesis in order to 
generate I130N receptor constructs. In order to avoid incidental mutations, after verifying the 
mutations with dideoxy sequencing, the mutated fragment was exchanged between the wild 
type and mutated portion with suitable restriction sites. Construction of  Epac-BRET was 
described previously (16). The cDNAs of the HA epitope-tagged wild-type and K44A mutant 
dynamins were subcloned into pcDNA3 vector, as previously described (31). The cDNA of C 
terminus of mRFP was fused to a cDNA of a nuclear localization signal [NLS; 
(DPKKKRKV)3]  with a linker (SGLRSRAQASNSRV) in a C1 plasmid.  
Cell culture and transfection 
Cell culture protocols and transfection of cells in 96-well plates were described previously 
(16). Briefly, the DNA amounts were either 0.25 μg receptor containing construct/well and 
0.25 μg BRET partner containing construct/well or in the case of co-transfection with three 
constructs of 0.2 μg receptor containing construct/well, 0.2 μg BRET partner containing 
construct/well and 0.2 μg untagged construct/well. The amount of Lipofectamine 2000 was 
0.5 μl/well.  
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BRET measurements  
BRET measurements were performed as described previously (16). We used either 
a Renilla luciferase-fused receptor as the energy donor and an eYFP-tagged protein as the 
acceptor or we used intramolecular BRET probe (cAMP measuring Epac-BRET). Dose-
response sigmoidal curve was generated using non-linear regression by GraphPad Prism 
software. The statistical analysis was carried out with two way ANOVA and Bonferroni post 
hoc test. 
Confocal microscopy 
The cells plated on polylysine-pretreated glass coverslips (3×10
5
 cells/35-mm dish) and were 
transiently transfected with the HA-tagged receptor constructs (1 μg of receptor/well; the 
amount of Lipofectamine 2000 was 4 μl/well.) and NLS-mRFP (0,125 µg/well). After 24 
hours, the cells were washed 3 times with ice cold 1% bovine serum albumin–containing 
modified Krebs-Ringer buffer (21) solution. For immunostaining, the anti-HA-Alexa 488 
mouse monoclonal antibodies were diluted to 1:250 and the cells were incubated for 30 
minutes on 4°C. Cells were washed and analyzed in ice-cold modified Krebs-Ringer buffer. 
For the co-localization studies, cells transiently transfected with the mVenus-tagged receptor 
constructs (1 μg of receptor/well; the amount of Lipofectamine 2000 was 4 μl/well.), NLS-
mRFP and MP-Cerulean (0,125 µg/well). The localization and distribution of the targeted 
probes were analyzed using a Zeiss LSM710 confocal laser-scanning microscope.  
Flow cytometry 
Cells were plated on glass coverslips (3×10
5
 cells/35-mm dish) and transiently transfected 
with the HA-tagged receptor constructs or pcDNA3.1. The cells were detached by Versene 
reagent treatment and were centrifuged. The cells were suspended in ice-cold PBS and 
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centrifuged at 4 
o
C. The cell pellets were suspended and incubated with diluted (1:100) anti-
HA-Alexa488 mouse monoclonal antibodies for 40 minutes on 4 
o
C. After the labeling period 
the cells were washed in ice-cold PBS. Flow cytometry measurements were performed with 
Beckman-Coulter SC. After measuring the fluorescent intensity of the cells, Gmean was 
calculated using WinMDI v2.9 (http://facs.scripps.edu). For the relative fluorescent intensity 
the background (pcDNA3.1) was subtracted and the data were normalized for the wild type 
receptor. Statistical analysis was carried out using two-way ANOVA.  
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Fig. 1 A: Pedigree of the family with X-linked congenital nephrogenic syndrome of 
inappropriate diuresis (NSIAD) due to a novel mutation. Arrow indicates the index 
patient. The hemizygous male is represented by a solid square. Heterozygous females are 
represented by open circles with a central dot. An open square indicates an unaffected male, 
genotyped wild type. Year of birth (b.) or death (d.) is placed below the symbol. A slash 
through the symbol indicates a deceased individual. Roman numerals denote the generation. 
Arabic numerals denote the individuals in each generation. B: Mutational analysis in 
AVPR2. Mutation analysis by direct DNA sequencing of PCR fragments from the proband 
and his family revealed a novel missense mutation p.Ile130Asn, c.389T>A in exon 2 of the 
AVPR2 gene. The proband showed a hemizygous mutation. His mother (II.2), his 
grandmother (I.2) and the proband´s sister (III.2) were heterozygous for the p.Ile130Asn 
mutation whereby their carrier status was confirmed.  
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Figure 2: Examination of the plasma membrane and intracellular expression of the 
I130N-V2R. 
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(A) Confocal microscopy analysis of HEK293 cells transiently expressing MP-Cerulean, 
NLS-mRFP and either mVenus-tagged WT-V2R or mVenus-tagged I130N-V2R. (B)  
Confocal microscopy analysis of HEK293 cells transiently expressing NLS-mRFP and either 
HA-tagged V2R or HA-tagged I130N-V2R. Immunofluorescent staining was implemented 
with anti-HA-Alexa488 mouse monoclonal antibodies. Scale bars represent 5 µm.  
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Figure 3: Measurement of the basal cAMP signal and the cAMP production after 
tolvaptan and AVP stimuli. HEK293 cells were transiently transfected with WT-V2R 
(square), I130N-V2R (circle) or N321K-V2R (triangle) and the Epac-BRET sensor. After 24 
h, the BRET measurements were implemented. Mean values ± SD are shown (n = 3, * p< 
0.05, *** p<0.001). (A) The cells were stimulated sequentially with 100 nM tolvaptan and 1 
μM AVP at the indicated time (filled marks). (B) The BRET ratios represent the last points 
before the next stimulus from Fig. 4A. (C) Dose response curve of wild type (square) and 
I130N-V2R (circle) upon tolvaptan treatment. The effect of the inverse agonist on the WT-
V2R and N321K-V2R expressing HEK293 cells was calculated as the BRET ratio difference 
between the ligand (stim) and the vehicle (nstim) treated cells at the first time points after the 
treatment. 
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Figure 4: Measurement of cells surface expression and internalization properties of 
I130N-V2R. (A) Cell surface expression values of the V2Rs were quantified after labeling 
with anti-HA-Alexa488 mouse monoclonal antibodies using flow cytometry determinations. 
After measuring the fluorescent intensity of the cells, Gmean was calculated. For the relative 
fluorescent intensity the background (pcDNA3.1) was subtracted and the data were 
normalized for the wild type receptor. Mean values ± SD are shown (n = 4, p<0.05). (B and 
C) HEK293 cells were transiently transfected with the plasmids of the indicated BRET 
partners (WT-V2R-Sluc or I130N-V2R-Sluc and MP-YFP) and after 24h BRET 
measurements were implemented. Mean values ± SD are shown (n = 3, p<0.05). (B) Cells 
were exposed to 100 nM tolvaptan (filled marks) or vehicle (open symbols) at the indicated 
time. (C) Cells were exposed to 1 μM AVP (filled marks) or vehicle (open symbols) at the 
indicated time.  
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Figure 5: Investigation of internalization properties of I130N-V2R. (A) Examination of 
β-arrestin binding properties of I130N-V2R. β-arrestin binding was measured with the 
transfection of wild type (square)- or I130N-V2R-mVenus (circle) and β-arrestin-Rluc 
plasmids. Cells were exposed either to 1µM AVP (filled symbols) or vehicle (open symbols) 
at the indicated time point. Mean values ± SD are shown (n = 3). (B) Examination of the 
effect of dominant negative dynamin on the internalization of I130N-V2R. HEK293 cells 
were transiently transfected with the plasmids of the indicated BRET partners (I130N-V2R-
Sluc and MP-YFP) and dynamin constructs (wild type or dominant negative) and after 24h 
BRET measurements were implemented. Cells were exposed to 100 nM tolvaptan (filled 
marks) or vehicle (open symbols) at the indicated time. Mean values ± S.E. are shown (n = 
3).  
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Figure 6: Schematic illustration of the consequences of I130N missense mutation in the 
V2R. Thickness of the arrows represent the magnitude of cAMP signal, internalization and  
β-arrestin binding. 
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Table 1. 
Characteristic Patient data Normal values 
Age at presentation 28 - 
Clinically significant findings palpitations - 
Blood pressure (mm HG) 
Systolic 
diastolic 
 
120 
80 
 
< 140 
< 90 
Serum and plasma analysis 
Sodium ( mmol/liter) 
 
121 
 
136-145 
Potassium ( mmol/liter ) 4.4 3.5-4.8 
Creatinine  ( mg/dl) 0.7 0.7-1.2 
Glomerular filtration rate (Mmol / min) 136 60 - 160 
Urea nitrogen ( mg/dl) 16.9 16.6 – 48.5 
ACTH (ng/l) 10.8 4.7-48.8 
Cortisol  (ng/ml) 59.5 23-194 
Aldosteron ( ng/l) 56 40 - 310 
Renin (ng/ml/h) 1.73 0.2 - 2.8 
Serum Osmolality (mOsm/kg) 205 280 - 300 
AVP (ng /l) < 0.6 0 – 7.8 
Urine analysis 
Urine Spezific weight ( g/l) 
 
1020 
 
1000 - 1030 
30 
 
Sodium excretion ( mmol/24h) 300.6 40 - 220 
Urine Osmolality ( mOsm/kg) 652 50 - 1200 
Table 1: Clinical characteristics of the index patient  
Table 2. 
Patient number Age (years) Serum sodium (mmol/l) AAVPR2 gene   
I.2 95 123 c.389T>A 
II.1 62 140 wt 
II.2 63 130 c.389T>A 
III.1 34 121 c.389T>A 
III.2 31 139 c.389T>A 
 
Table 2: Clinical and laboratory characteristics of the family members 
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Supplementary figure 1: Measurement of the cAMP production after AVP and 
forskolin stimulations. HEK293 cells were transiently transfected with WT-V2R and the 
Epac-BRET sensor. After 24 h, the BRET measurements were implemented. Mean values ± 
S.E. are shown (n = 3). The cells were stimulated sequentially with 1 μM AVP and 10 μM 
forskolin at the indicated time (filled marks). 
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Supplementary figure 2: Relative Sluc counts of the WT-V2R and I130N-V2R measured 
after cell permeable substrate coelenterazine treatment. The Sluc counts of the tagged 
receptors were obtained from the BRET experiment in Fig 4B. The averages of the counts 
were calculated from the non-stimulated Sluc counts (before tolvaptan or vehicle stimulation) 
of the wells in the first two cycles. The averages were normalized in each experiment the 
WT-V2R. Mean values ± S.E. are shown (n = 3). 
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Supplementary figure 3: Control measurements for the examination of the effect of 
dominant negative dynamin on the internalization of I130N-V2R. HEK293 cells were 
transiently transfected with the plasmids of the indicated BRET partners (I130N-V2R-Sluc or 
WT-V2R-Sluc and MP-YFP) and wild type dynamin constructs (dynamin1 or -2) or empty 
pcDNA3.1 vector and after 24h BRET measurements were implemented. Mean values ± S.E. 
are shown (n = 3). 
 
 
 
 
